Teriflunomide Tablet
Product Images NDC 59651-055

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 59651-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Teriflunomide Fig1)

A line graph depicting disability progression sustained for 12 weeks over a period of 108 weeks, comparing placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. The y-axis shows the percentage of disability progression, and the x-axis shows the number of weeks. The chart includes a risk table below indicating the number of participants at various time points for each group.*

FDA Label Image

Figure 2 (Teriflunomide Fig2)

A line graph showing the percentage of patients with disability progression sustained for 12 weeks over time (up to 108 weeks) for three groups: Placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. The graph includes a table below listing the number of patients at risk in each group at various weekly intervals. The 14 mg Teriflunomide group shows statistically significant differences compared to Placebo (p < 0.05).*

FDA Label Image

Package Label-principal Display Panel (7 mg)

Label for Teriflunomide 7 mg oral tablets by Aurobindo Pharma Limited, package containing 30 tablets. The label includes drug name, strength, storage instructions, usual dosage directions, pharmacist dispensing note, distributor details, and a barcode. It specifies prescription use only and contains a designated coding area for additional printing.*

FDA Label Image

Package Label-principal Display Panel (7 mg)

Packaging label for Teriflunomide Tablets 7 mg oral tablets, distributed by Aurobindo Pharma USA, Inc. The box contains 28 tablets provided as 2 blisters of 14 tablets each. The label includes storage instructions, usual dosage guidance, and a pharmacist medication guide note, with branding for Aurobindo and an NDC number 59651-054-28.*

FDA Label Image

Package Label-principal Display Panel (14 mg)

Teriflunomide Tablets 14 mg oral tablets label from Aurobindo Pharma Limited. The label includes storage instructions (20° to 25°C), dosage directions of one tablet once daily, a warning to keep out of reach of children, and distributor information for Aurobindo Pharma USA, Inc. The package contains 30 tablets.*

FDA Label Image

Package Label-principal Display Panel (14 mg)

Packaging label for Teriflunomide Tablets 14 mg oral tablets, manufactured by Aurobindo Pharma Limited. The carton contains 28 tablets, arranged in 2 blisters of 14 tablets each. Label panels include storage instructions, dosing note, warning to keep out of reach of children, and distributor information for Aurobindo Pharma USA, Inc.*

FDA Label Image

Chemical Structure (Teriflunomide Str)

Chemical structure of the active ingredient Teriflunomide, showing its molecular arrangement with functional groups and atoms typical of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.